Taube Philanthropies has announced a $3 million grant in support of research related to Huntington's disease.
The grant will support a multiyear collaboration between Stanford Medicine and the Gladstone Institutes focused on the use of gene editing and stem cell therapies to develop treatments and, eventually, a cure for Huntington's disease, a genetic neurodegenerative disease that causes the progressive breakdown of nerve cells in the brain, leading to premature death. Researchers Matthew Porteus, MD, PhD, associate professor of pediatrics at Stanford Medicine; Frank Longo, MD, PhD, professor of neurology at Stanford Medicine; and Steve Finkbeiner, MD, PhD, of the Gladstone Institutes' Taube-Koret Center for Neurodegenerative Disease Research will collaborate with clinicians at the UCSF Memory and Aging Center under the direction of Bruce Miller, MD, PhD. Harvey Cohen, MD, PhD, a professor of pediatrics at Stanford Medicine, organized the team of researchers, while Porteus will lead the effort.
The grant from Taube Philanthropies continues its commitment to finding treatments and a cure for neurodegenerative diseases. Over the past twelve years, the organization has donated more than $5 million to the Gladstone Institutes and $1 million to Stanford Medicine for related research.
"Huntington's disease is a cruel genetic disorder that robs its victims of physical and mental control," said Tad Taube, founder and chair of Taube Philanthropies. "The time and research that Stanford, UCSF, and Gladstone Institutes have committed to this cause is remarkable. I am proud to play a contributing role in the important research being conducted at these institutions and look forward to results that have the potential to transform the lives of Huntington's disease patients."